New Platinum Derivatives Selectively Cause Double-Strand DNA Breaks and Death in Naïve and Cisplatin-Resistant Cholangiocarcinomas

Researchers designed and evaluated two novel compounds, Aurkine 16 and Aurkine 18, for their antitumor effects in both naïve and cisplatin-resistant cholangiocarcinoma cells, cancer-associated fibroblasts, healthy cholangiocytes, and in vivo models.